EX-4.2





 Exhibit 4.2 

Execution Version 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 15th day of January, 2021, by and among TScan Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is
referred to in this Agreement as an “Investor”. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Series B Preferred Stock, the Series A
Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Amended and Restated Investors’ Rights Agreement,
dated as of July 11, 2019, by and among the Company and such Existing Investors party thereto (as amended, the “Prior Agreement”) 

WHEREAS, the Existing Investors that are a party to this Agreement and the Prior Agreement are collectively holders of at least 59% of
the then outstanding Registrable Securities (as defined in the Prior Agreement) (voting together as a single class and not as separate series and on an as-converted to Common Stock basis) held by the Existing
Investors (collectively, the “Requisite Stockholders”), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the
Prior Agreement; 
 WHEREAS, the Company and certain of the Investors are parties to that certain Series C Preferred Stock Purchase
Agreement of even date herewith (the “Purchase Agreement”), under which the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by the Company, such Investors and the
Requisite Stockholders; and 
 WHEREAS, in order to induce the Company and certain of the Investors to enter into the Purchase
Agreement and to purchase shares of Series B Preferred Stock thereunder, the parties desire to enter into this Agreement to govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to
receive certain information from the Company, and to participate in future equity offerings by the Company, and certain other matters as set forth in this Agreement. 

NOW, THEREFORE, the Company and the undersigned Requisite Stockholders hereby agree to amend and restate the Prior Agreement in its
entirety as set forth herein, and the parties to this Agreement hereby further agree as follows: 
 1. Definitions. For
purposes of this Agreement: 
 1.1 “6 Dimensions” means 6 Dimensions Capital, L.P., 6 Dimensions Affiliates Fund, L.P. and
their Affiliates. 












 1.2 “Affiliate” means, with respect to any specified Person, (i) any
other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund or
other investment fund now or hereafter existing that is controlled by one or more general partners or managing members or investment advisers of, or shares the same management company or investment adviser with, such Person, and with respect to an
Investor, (ii) any Person directly or indirectly managed or advised by the Investor or an entity referred to in (i) above. For the avoidance of doubt, Seth Rudnick or his trust, Seth A Rudnick 2014 Irrevocable GST Trust, and Pitango (as
defined herein) shall be deemed Affiliates of one another. 
 1.3 “Baker Bros.” means 667, L.P., Baker Brothers Life
Sciences, L.P. and their respective Affiliates. 
 1.4 “Bessemer” means Bessemer Venture Partners IX L.P., Bessemer
Venture Partners IX Institutional L.P. and their Affiliates. 
 1.5 “Bessemer Director” means the Series A Director
designated by Bessemer pursuant to the Voting Agreement. 
 1.6 “BlackRock” means BlackRock Health Sciences Trust II and
its Affiliates. 
 1.7 “Board” means the Company’s Board of Directors. 

1.8 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 

1.9 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in a business that competes with the Company’s business, but shall not include any financial investment firm or collective investment
vehicle that, together with its Affiliates, holds less than twenty percent (20)% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any
Competitor. For the avoidance of doubt, Longwood, Baker Bros., Hillhouse, RA Capital, BlackRock, Bessemer, Novartis, GV, 6 Dimensions, NIBR, Pitango Healthtech Fund I, L.P., Pitango Healthtech Principals Fund I, L.P. (collectively,
“Pitango”) and Astellas Venture Management, LLC (“AVM”), and each of their respective Affiliates, shall not at any time be deemed to be a Competitor. 

1.10 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject
under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state
therein a material fact required 

  
 2 













 
to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or
Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.11 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.12 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.13 “Excluded Registration”
means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration
in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.14 “FOIA Party” means a Person that, in the reasonable determination of the Board of Directors, may be subject to, and
thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law,
any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.15 “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.16 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.17 “GAAP” means generally accepted
accounting principles in the United States as in effect from time to time. 
 1.18 “GV” means GV 2017, L.P., GV 2019, L.P.
and their Affiliates. 
 1.19 “Hillhouse” means JMD II Holdings Limited and its Affiliates. 

1.20 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

  
 3 













 1.21 “Immediate Family Member” means a child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including, adoptive relationships, of a
natural person referred to herein. 
 1.22 “Initiating Holders” means, collectively, Holders who properly initiate a
registration request under this Agreement. 
 1.23 “IPO” means the Company’s first underwritten public offering of
its Common Stock under the Securities Act. 
 1.24 “Key Employee” means any executive-level employee
(including vice-president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.25 “Longwood” means Longwood Fund IV, L.P. and its Affiliates. 

1.26 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
4,329,004 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). Notwithstanding the foregoing, Baker Bros. shall be deemed to be a
Major Investor. 
 1.27 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.28 “NIBR” means Novartis Institutes for Biomedical Research, Inc. and its Affiliates. 

1.29 “Novartis” means Novartis Bioventures Ltd. and its Affiliates. 

1.30 “Novartis Director” means the Series A Director designated by Novartis pursuant to the Voting Agreement. 

1.31 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.32 “Preferred Director” means any Series A Director, Series B Director or Series C Director. 

1.33 “Preferred Stock” means shares of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C
Preferred Stock. 

  
 4 













 1.34 “RA Capital” means RA Capital Healthcare Fund, L.P., RA Capital Nexus
Fund II, L.P. and their Affiliates. 
 1.35 “Registrable Securities” means (i) the Common Stock issuable or issued
upon conversion of the Preferred Stock, (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the
Company, acquired by the Investors after the date hereof and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with
respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) or (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this
Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.36 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.37 “Requisite Investor Directors” means, the affirmative vote of a majority of the then-seated Preferred Directors (a
majority of which majority shall be comprised of a combination of the Novartis Director, the Bessemer Director, either Series B Director and the Series C Director). 

1.38 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in
Subsection 2.12(b) hereof. 
 1.39 “SEC” means the Securities and Exchange Commission. 

1.40 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.41 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.42 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.43 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

  
 5 













 1.44 “Series A Director” means any director of the Company that the
holders of the Series A Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 
 1.45
“Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 

1.46 “Series B Director” means any director of the Company that the holders of the Series B Preferred Stock are entitled to
elect pursuant to the Company’s Certificate of Incorporation. 
 1.47 “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.0001 per share. 
 1.48 “Series C Director” means any director of
the Company that the holders of the Series C Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 

1.49 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.0001 per share.

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) three (3) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least thirty-five percent (35%) of the Registrable
Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least thirty-five (35%) of the Registrable Securities then outstanding and held by such Holders
having an anticipated aggregate offering price of at least $10,000,000, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other
than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration
statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of Registrable Securities then outstanding that the Company file a Form S-3 registration statement with
respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3,000,000, then the Company shall (i) within ten (10) days after the date such request is
given, give a Demand Notice to all Holders other than the 

  
 6 













 
Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for such registration statement to either become
effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other
similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with
requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time period with respect to filing or effectiveness thereof shall be tolled correspondingly, for
a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided
further that the Company shall not register any securities for its own account or that of any other stockholder during such sixty (60) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations
pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made
pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) during the period that is thirty (30) days before the Company’s good
faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable
efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such
request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders
withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement
shall be counted as “effected” for purposes of this Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection 2.1(c), then the
Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 

  
 7 













 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements.

 (a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected
by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; provided, however, that no Holder (or any of
their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter into the underwriting agreement and to such Holder’s intended
method of distribution, and the liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this Subsection 2.3,
if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

  
 8 













 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities
included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the
determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of
Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes
of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of
Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

  
 9 













 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to an additional twenty (120) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 10 













 (h) promptly make available for inspection by the selling Holders, any underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate
documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in
each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2 or pursuant to an IPO, including all registration,
filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders or, in the case of an IPO, one counsel to the
Investors (“Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon
the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections
2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from
that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall 

  
 11 













 
not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to
Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company
be liable for any Damages only to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration and has not been corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim; and each such selling Holder will pay to
the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred;
provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent


  
 12 













 
of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or
contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder except
to the extent such information has been corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the
indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified 

  
 13 













 
party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such
case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control; provided, however, that any matter expressly provided for or addressed by the foregoing provisions that is not expressly provided for or addressed by the underwriting agreement shall be
controlled by the foregoing provisions. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the
underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the
Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those terms
are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent


  
 14 













 
annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder
of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on Subsequent
Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Requisite Preferred Holders, enter into any agreement with any holder or prospective holder of any securities of the
Company that (i) would allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only
to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any
securities held by such holder or prospective holder; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Subsection 6.9.

 2.11 “Market Stand-off” Agreement. Each Holder
hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other
equity securities under the Securities Act on a registration statement on Form S-1 and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer;
pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common
Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock, in each case, held immediately before the effective date of the registration statement for such offering or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be
settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors, and all stockholders (together with such
stockholder’s Affiliates) owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock), are subject to the same restrictions. The
underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such 

  
 15 













 
registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all
of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements, unless otherwise approved by the Requisite Preferred Holders (as defined
below). In the event that any underwriter requests any Major Investor to sign a lock-up agreement (a “Major Investor Lock-Up Agreement”), and any
director, officer, or stockholder (together with such stockholder’s Affiliates) owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred
Stock) enters into a lock-up agreement with the underwriter with terms that are more favorable to such stockholder than are afforded to any Major Investor in such Major Investor’s Major Investor Lock-Up Agreement, the Company shall use its best efforts to require the underwriters to include such more favorable terms in each Major Investor Lock-Up Agreement. The
Company shall notify the Major Investors if it is aware of any lock-up agreements relating to the Company with more favorable terms than the Major Investor Lock-Up
Agreement. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case,
to be bound by the terms of this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 16 













 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, or following the
IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer; provided that no notice shall be required in connection if the intended
sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at
such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be
effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a
recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted
Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given
by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted
Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted
Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book
entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the closing of a Deemed
Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, in which the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities, or if the
Investors receive registration rights from the acquiring company or other successor to the Company reasonably comparable to those set forth in this Section 2; 

  
 17 













 (b) such time following the IPO as SEC Rule 144 or another similar exemption under the
Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c) the third anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board has not reasonably
determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event within one hundred twenty
(120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for
such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined below) for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements
audited and certified by independent public accounts of nationally or regionally recognized standing selected by the Company; 
 (b) as
soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter,
and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), approved by the Board, including the Requisite Investor Directors (as defined below), and prepared on a monthly basis, including balance sheets, income statements, and statements of
cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

  
 18 













 (e) such other information relating to the financial condition, business, prospects,
capitalization or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement in a form reasonably acceptable to the Company); or (ii) the disclosure
of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has
any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries.
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company
may cease providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it must do
so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively
employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The
Company shall permit each Major Investor (provided that the Board has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its
books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company
shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement in form reasonably acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel). 

3.3 Observer Rights. 

(a) As long as Longwood owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a
representative of Longwood to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
(A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable
confidentiality agreement in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

  
 19 













 (b) As long as Bessemer owns any shares of Preferred Stock (or Common Stock issued upon
conversion thereof), the Company shall invite a representative of Bessemer to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies
of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence
and trust and to act in a fiduciary manner with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such
information or attendance at such meeting could (A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade
secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result
in a conflict of interest. 
 (c) As long as Novartis owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof),
the Company shall invite a representative of Novartis to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to
act in a fiduciary manner with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could (A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless
covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict
of interest. 
 (d) As long as 6 Dimensions owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the
Company shall invite a representative of 6 Dimensions to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to
act in a fiduciary manner with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could (A) adversely affect the attorney-client 

  
 20 













 
privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable
confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

(e) As long as NIBR owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a
representative of NIBR to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
(A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable
confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

(f) As long as Pitango owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a
representative of Pitango to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
(A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable
confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

(g) As long as AVM owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a
representative of AVM to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; and (ii) the Company reserves the right to withhold any information 

  
 21 













 
and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could (A) adversely affect the attorney- client privilege
between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the
Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

(h) As long as Baker Bros. owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a
representative of Baker Bros. to attend all meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with
respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
(A) adversely affect the attorney-client privilege between the Company and its counsel (based upon advice from the Company’s qualified outside counsel), (B) result in disclosure of trade secrets (unless covered by an enforceable
confidentiality agreement, in a form reasonably acceptable to the Company, it being understood that Section 3.5 of this Agreement shall be considered a form acceptable to the Company) or (C) result in a conflict of interest. 

3.4 Termination of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and
Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO, as such term is defined in the Company’s Certificate of Incorporation, or (ii) upon a Deemed
Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 3.5
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company or to enforce its
rights) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or
becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential
information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may
disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection 

  
 22 













 
with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the
provisions of this Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs
such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such
Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it
deems appropriate, among (i) itself and (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a
Competitor, unless such party’s purchase of New Securities is otherwise consented to by the Board, (y) agrees to enter into this Agreement and each of the Amended and Restated Voting Agreement (the “Voting Agreement”) and
Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such
agreement (provided that any FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1 and 3.2 hereof). 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to
purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase 

  
 23 













 
or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by
the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by
such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by all Fully
Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of
initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities referred to in the Offer Notice are not
elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Major Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer in this Subsection
4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation) and (ii) shares of Common Stock issued in the IPO and (iii) the issuance of shares of Preferred Stock to the
Investors pursuant to Subsection 1.3 of the Purchase Agreement. 
 4.2 Termination. The covenants set forth in Subsection
4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO, as such term is defined in the Company’s Certificate of Incorporation, or (ii) upon a Deemed Liquidation Event,
as such term is defined in the Company’s Certificate of Incorporation, in which the consideration received by the Major Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities, or if the Major
Investors receive participation rights from the acquiring company or other successor to the Company reasonably comparable to those set forth in this Section 4, whichever event occurs first. 

5. Additional Covenants. 

5.1 Director and Officer Insurance. The Company shall use commercially reasonable efforts to maintain its Directors and
Officers liability insurance with coverage at least as is presently in effect until such time as the Board (including the Requisite Investor Directors) determines that such insurance should be discontinued or reduced. The Directors and Officers
liability insurance policy shall not be cancelable by the Company without prior approval by the Board, including the Requisite Investor Directors. Notwithstanding any other provision of this Section 5.1 to the contrary, for
so long as a Preferred Director is serving on the Board, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least three million ($3,000,000) unless otherwise approved by such Preferred
Director. 

  
 24 













 5.2 Investment Bankers. The Company shall not hire, fire or amend the terms of
engagement of any investment bankers without the prior written approval of the Requisite Preferred Holders. 
 5.3 Employee
Agreements. Unless otherwise approved by the Board (including the Requisite Investor Directors (as defined below)), the Company will cause (i) each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or
any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure, proprietary rights assignment and non-solicitation agreement
and (ii) each Key Employee to enter into a non-competition agreement, in each case substantially in forms approved by the Board (including the Requisite Investor Directors (as defined below)). In
addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any provision of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of
the Board, which consent shall include the Requisite Investor Directors. 
 5.4 Employee Stock. Unless otherwise approved by
the Board, including the Requisite Investor Directors, all employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to
execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Subsection 2.11. Without the prior approval by the Board, including the Requisite Investor Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part,
any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this Subsection 5.3. In addition, unless otherwise approved by the Board,
including the Requisite Investor Directors, the Company shall not offer or allow any acceleration of vesting and shall retain (and not waive) a “right of first refusal” on employee transfers until the Company’s IPO and shall
have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.5 Matters
Requiring Investor Director Approval. 
 (a) So long as the holders of Preferred Stock are entitled to elect a Preferred Director, the
Company hereby covenants and agrees with each of the Investors that it shall not and it shall cause each of its direct and indirect subsidiaries not to, without approval of the Board, which approval must include the affirmative vote of the Requisite
Investor Directors: 
 (i) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any
subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

  
 25 













 (ii) make, or permit any subsidiary to make, any loan or advance to any Person, including,
without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; 

(iii) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (iv) make any investment inconsistent with any
investment policy approved by the Board other than investments in prime commercial paper, money market funds, certificates of deposit in any United States bank having a net worth in excess of $100,000,000 or obligations issued or guaranteed by the
United States of America; 
 (v) incur any aggregate indebtedness in excess of $250,000 that is not already included in a budget approved
by the Board, other than trade credit incurred in the ordinary course of business; 
 (vi) otherwise enter into or be a party to any
transaction with any director, officer, consultant or employee of the Company, or any significant stockholder of the Company, or any “associate” (as defined in Rule 12b-2 promulgated under the
Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan providing payments to employees in connection with a Deemed Liquidation Event, as such term is defined in the Company’s Certificate
of Incorporation, except for transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the disinterested members
of the Board who have no direct economic interest in the transaction and no affiliation (other than representation on the Board) with any entity that (i) is a party to the transaction or (ii) is affiliated with a party to the transaction;

 (vii) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to
executive officers; 
 (viii) change the principal business of the Company, enter new lines of business, or exit the current line of
business; 
 (ix) sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in
the ordinary course of business; or 
 (x) enter into any corporate strategic relationship involving the payment, contribution, or
assignment by the Company or to the Company of money or assets greater than $500,000, except for transactions in the ordinary course of business. 

  
 26 













 (b) Notwithstanding anything herein to the contrary, prior to approving any action or
waiver that requires the approval of the Requisite Investor Directors pursuant to this Agreement or the Company’ Certificate of Incorporation (an “Investor Director Approval Action”), if the Series C Director seat is vacant,
then the Company shall provide Baker Bros. no less than five business days’ written notice prior to considering such Investor Director Approval Action, and the Board shall not consider such Investor Director Approval Action during such five
business day period. If, during such five business day period, Baker Bros. notifies the Company, in writing, of its designation of a Series C Director, the Company covenants and agrees that it shall not take the applicable Investor Director Approval
Action unless such Series C Director is seated on the Board and has voted on such applicable Investor Director Approval Action. 
 5.6
Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board shall meet in person or by video conference at least quarterly in accordance with an agreed-upon schedule. The Company shall
reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with
attending meetings of the Board. Any Board committee shall include at least two (2) Preferred Directors (which Preferred Directors, for the avoidance of doubt, shall not include more than one Series A Director designated by Longwood). The
Series C Director shall have the right to sit on any committee of the Board. 
 5.7 Successor Indemnification. If the Company or any
of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 5.8 Investor Counsel. At the outset of considering a
transaction which, if consummated would constitute a Sale of the Company (as defined in the Voting Agreement (as defined in the Purchase Agreement)), the Company shall obtain the ability to share with the counsel(s) for the Major Investors
(“Investor Counsel”) (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other
transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of
the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such
transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other
reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In
the event that one or more of the other party or parties to such transactions 

  
 27 













 
require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever
information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the
clients of Investor Counsel. 
 5.9 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the
directors nominated to serve on the Board by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of
their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any obligation of
the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such
Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by the Company’s
Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and, (c) that it irrevocably
waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or
payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party
beneficiaries of this Subsection 5.9 and shall have the right, power and authority to enforce the provisions of this Subsection 5.9 as though they were a party to this Agreement. 

5.10 Right to Conduct Activities. The Company hereby agrees and acknowledges Longwood, Baker Bros., Hillhouse, RA Capital, BlackRock,
Bessemer, Novartis, GV, 6 Dimensions, Pitango, AVM and their Affiliates (including any affiliated advisors and funds irrespective of whether such affiliated advisors or funds fit within the definition of “Affiliate” pursuant to this
Agreement) are professional investment managers and/or funds or venture investment arms of their Affiliates, and as such, invest in numerous portfolio companies or have Affiliates, some of which may be deemed competitive with the Company’s
business (as conducted or proposed to be conducted). Neither Longwood, Baker Bros., Hillhouse, RA Capital, BlackRock, Bessemer, Novartis, GV, 6 Dimensions, Pitango, AVM nor any of their Affiliates (including any affiliated advisors and funds
irrespective of whether such affiliated advisors or funds fit within the definition of “Affiliate” pursuant to this Agreement) shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by Longwood,
Baker Bros., Hillhouse, RA Capital, BlackRock, Bessemer, Novartis, GV, 6 Dimensions, Pitango, AVM or any of their Affiliates (including any affiliated advisor or fund irrespective of whether such affiliated advisor or fund fits within the definition
of “Affiliate” 

  
 28 













 
pursuant to this Agreement) in any entity competitive to the Company or the activities of their Affiliates, or (ii) actions taken by any advisor, partner, officer or other representative of
Longwood, Baker Bros., Hillhouse, RA Capital, BlackRock, Bessemer, Novartis, GV, 6 Dimensions, Pitango, AVM or any of their Affiliates (including any affiliated advisor or fund irrespective of whether such affiliated advisor or fund fits within the
definition of “Affiliate” pursuant to this Agreement) to assist any such competitive company, whether or not such action was taken as a board member of such competitive company, or otherwise; provided, however, that the foregoing shall not
relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any
liability associated with a breach of his or her fiduciary duties to the Company. 
 5.11 Real Property Holding Corporation. If at
any time the Company determines that it is a “United States real property holding corporation” (a “USRPHC”) as defined in the Code and any applicable regulations promulgated thereunder, it shall promptly inform the
Investor in writing of such determination. In addition, upon the Investor’s request, the Company shall promptly determine whether or not it is a USRPHC and shall promptly inform Longwood, Baker Bros., Bessemer, Novartis, GV, 6 Dimensions,
Pitango and AVM in writing of such determination. 
 5.12 Export. The Company agrees to inform Longwood, Baker Bros., RA Capital,
BlackRock, Bessemer, Novartis, GV, 6 Dimensions, Pitango, AVM and Hillhouse if the Company does conduct, or expects to conduct, operations from or do business directly or indirectly in or with Cuba, North Korea, Iran, Syria, or the Crimea region of
Ukraine. 
 5.13 Munitions. The Company covenants not to control any weapon or explosive device, nuclear or otherwise. 

5.14 Anti-corruption. The Company covenants to maintain systems or internal controls (including, but not limited to, accounting
systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law (such as Part 12 of the United States Anti-Terrorism, Crime and Security Act of 2001; the United States
Money Laundering Control Act of 1986; the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001; the United States Foreign Corrupt Practices Act, as amended; and laws applicable in the United Kingdom that
prohibit bribery, corrupt practices or money laundering, including, for the avoidance of doubt, the Bribery Act 2010). 
 5.15
Subsidiary Governance. No subsidiary of the Company shall take any action without the approval of the Board to the extent approval of the Board would be required in the event such action was to be taken by the Company itself, including the
requisite groups of directors whose approval would be required in the event such action was to be taken by the Company itself. 

  
 29 













 5.16 Interested Transaction Approvals. The Company will not enter into any
transaction with an Investor or any person that is employed by, consults with, or is otherwise affiliated with an Investor without the approval of a majority of the disinterested members of the Board who have no direct economic interest in the
transaction and no affiliation (other than representation on the Board) with any entity that (i) is a party to the transaction or (ii) is affiliated with a party to the transaction. 

5.17 CFIUS Matters. If, to the knowledge of the Company, at any time the Company (i) is deemed to be a “TID U.S.
business” as that term is defined in 31 C.F.R. § 800.248 or (ii) engages in the design, fabrication, development, testing, production or manufacture of “critical technologies” as defined by 31 C.F.R. § 800.215, as
amended, then the Company shall provide written notice to Longwood, Baker Bros., RA Capital, BlackRock, Bessemer, Novartis, GV, NIBR, 6 Dimensions, Pitango, AVM and Hillhouse within 10 days of knowledge of such designation or engagement. 

5.18 Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Series A Preferred
Stock and Series B Preferred Stock, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business
stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board determines, in its good-faith business judgment, that such qualification is inconsistent with the best
interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated
thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and what portion
of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s possession as
is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. 

5.19 Termination of Covenants. All of the covenants set forth in this Section 5, except for Subsections
5.7, 5.8 and 5.9, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate
of Incorporation, whichever event occurs first. 
 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
or (iii) after such transfer, holds at least 500,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x) the Company is, within a reasonable time after 

  
 30 













 
such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of
Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual
Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a
single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this
Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law
principles that would result in the application of any law other than the law of the State of Delaware. 
 6.3 Counterparts. This
Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. 
 6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and if not sent during normal business hours, then on
the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally
recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on
Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance
with this Subsection 6.5. If notice is given to the Company, a copy 

  
 31 













 
shall also be sent to Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, One Marina Park Drive, Suite 900, Boston, MA 02210, Attention: Timothy H. Ehrlich; and if notice is
given to Investors, a copy (which shall not constitute notice) shall also be given to Cooley LLP, 500 Boylston Street, 14th Floor, Boston, MA 02116, Attention: Joshua Rottner and to Faber,
Daeufer & Itrato PC, 890 Winter Street, Suite 315, Waltham, MA 02451, Attention: Kurt Machemer and to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attention: Jason Kropp, Email: Jason.Kropp@wilmerhale.com.

 (b) Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware
General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address set forth below such
Investor’s name on Schedule A hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned or undeliverable for any
reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each Investor agrees
to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the then outstanding Registrable Securities (voting
together as a single class and not as separate series and on an as-converted to Common Stock basis) (the “Requisite Preferred Holders”); provided that the Company may in its sole
discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver);
and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended,
modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the
same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that
certain Investors may, nonetheless, by agreement with the Company, purchase securities in such transaction; provided, however, that if any Major Investor (or Affiliate of a Major Investor) is allowed to participate in any such transaction or
financing, then each other Major Investor will be offered the opportunity to participate on the same basis (although proportionate to their respective holdings of Registrable Securities)), (b) Subsections 3.1 and 3.2,
Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or 

  
 32 













 
waived without the written consent of the holders of at least a majority of the Registrable Securities then outstanding and held by the Major Investors, (c) Subsection 3.3(a) and this
clause (c) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Longwood for so long as Longwood holds any Registrable Securities, (d) Subsections 3.3(b), 5.10,
5.11, 5.12, 5.13, 5.14, 5.15, 5.16 and this clause (d) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Bessemer for so
long as Bessemer holds any Registrable Securities, (e) Subsection 3.3(c) and this clause (e) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Novartis for so long as
Novartis holds any Registrable Securities, (f) Subsection 3.3(d) and this clause (f) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of 6 Dimensions for so long as 6
Dimensions holds any Registrable Securities, (g) Subsections 3.3(e), 5.17 and this clause (g) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of NIBR for so long as
NIBR holds any Registrable Securities, (h) Subsection 3.3(f) and this clause (h) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Pitango for so long as Pitango holds
any Registrable Securities, (i) Subsections 3.3(g), 5.10, 5.11, 5.12, 5.17 and this clause (i) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent
of AVM for so long as AVM holds any Registrable Securities, (j) Subsections 1.25 (as it relates to Baker Bros.), 3.3(h), 5.10, 5.11, 5.12, 5.17 and this clause (j) of this Subsection 6.6 may
not be amended, modified, terminated or waived without the written consent of Baker Bros. for so long as Baker Bros holds any Registrable Securities, (k) Subsections 5.10, 5.12, 5.17 and this clause (k) of this
Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Hillhouse for so long as Hillhouse holds any Registrable Securities, (l) Subsections 5.10, 5.12, 5.17 and this clause
(l) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of RA Capital for so long as RA Capital holds any Registrable Securities, and (m) Subsections 5.10, 5.12,
5.17 and this clause (m) of this Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of BlackRock for so long as BlackRock holds any Registrable Securities. Notwithstanding the foregoing,
Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties, and Schedule A hereto may also
be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. The Company
shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination,
or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement,
in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 

  
 33 













 6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained in any other section of this Agreement, subject to
Section 3.3 of Article FOURTH, Part B of the Restated Certificate, if the Company issues additional shares of the Company’s Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of
such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action
or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) together with the other Transaction Documents (as
defined in the Purchase Agreement) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing
between the parties is expressly canceled. 
 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER 

  
 34 













 
COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER
WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such
party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter
jurisdiction. 
 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under
this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such
breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.13 Effect on Prior Agreement.
Upon the effectiveness of this Agreement, the Prior Agreement shall be superseded and replaced in its entirety by this Agreement and shall be of no further force or effect. 

[Remainder of Page Intentionally Left Blank] 

  
 35 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	TSCAN THERAPEUTICS, INC.
		
	By:	 	/s/ David Southwell


 
			
	Name:	 	David Southwell
	Title:	 	Chief Executive Officer


 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 












 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	667, L.P.
	
	BY: BAKER BROS. ADVISORS LP,
	management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.


  

			
	By:	 	/s/ Scott Lessing


 
			
	Name:	 	Scott L. Lessing
	Title:	 	President


  

			
	BAKER BROTHERS LIFE SCIENCES, L.P.
	
	By: BAKER BROS. ADVISORS LP,
	 management company and investment adviser to

Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers
Life Sciences, L.P., and not as the general partner.



  

			
	By:	 	/s/ Scott Lessing


 
			
	Name:	 	Scott L. Lessing
	Title:	 	President


 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 












 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	JMD III HOLDINGS LIMITED
		
	By:	 	/s/ Colm O’Connell


 
			
	Name:	 	Colm O’Connell
	Title:	 	Authorized Signatory


 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 












 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	BLACKROCK HEALTH SCIENCES TRUST II
	
	By: BlackRock Advisors, LLC, its Investment Adviser


  

			
	By:	 	/s/ Hongying Erin Xie


 
			
	Name:	 	Hongying Erin Xie
	Title:	 	Managing Director


 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 












 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	 By: RA Capital Healthcare Fund GP, LLC

Its General Partner



  

			
	By:	 	/s/ Rajeev Shah


 
			
	Name:	 	Rajeev Shah
	Title:	 	Manager


  

			
	Address: RA Capital Management, L.P.
		 	 200 Berkeley Street
 18th Floor
 Boston, MA 02116

Attn: General Counsel



 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 












 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	RA CAPITAL NEXUS FUND II, L.P.
		
	By:	 	RA Capital Nexus Fund II GP, LLC
		
	Its:	 	General Partner


 
			
		
	By:	 	/s/ Rajeev Shah


 
			
	Name:	 	Rajeev Shah
	Title:	 	Manager


 
			
		
	Address:	 	RA Capital Management, L.P.
		 	200 Berkeley Street
		 	18th Floor
		 	Boston, MA 02116
		 	Attn: General Counsel



  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GEBRIAN FAMILY TRUST


 
			
		
	By:	 	/s/ Tom Millett


 
			
	Name:	 	Tom Millett
	Title:	 	Trustee



  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	TIMOTHY BARBERICH
		
	By:	 	/s/ Timothy Barberich


  

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	LONGWOOD FUND IV, L.P.


 
			
	
	By: Longwood Fund IV GP, LLC, its General Partner


 
			
		
	By:	 	/s/ John Lawrence


 
			
	Name:	 	John Lawrence
	Title:	 	CFO



  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	BESSEMER VENTURE PARTNERS IX, L.P.
	BESSEMER VENTURE PARTNERS IX INSTITUTIONAL L.P.
		
	By:	 	Deer IX & Co. L.P., their General Partner


 
			
	By:	 	Deer IX & Co. Ltd., its General Partner


 
			
		
	By:	 	/s/ Scott Ring


 
			
	Name:	 	Scott Ring
	Title:	 	General Counsel



  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	NOVARTIS BIOVENTURES LTD.
		
	By:	 	/s/ Bart Dzikowski
	Name:	 	     Bart Dzikowski
	Title:	 	Secretary of the Board


  

			
		
	By:	 	/s/ Beat Steffen
	Name:	 	     Beat Steffen
	Title:	 	



  

SIGNATURE PAGE TO AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	6 DIMENSIONS CAPITAL, L.P.
	
	By: 6 Dimensions Capital GP, LLC, its General Partner
		
	By:	 	/s/ Christina Chung
	Name:	 	Christina Chung
	Title:	 	Chief Financial Officer


  

			
	6 DIMENSIONS AFFILIATES FUND, L.P.
	
	By: 6 Dimensions Capital GP, LLC, its General Partner
		
	By:	 	/s/ Christina Chung
	Name:	 	Christina Chung
	Title:	 	Chief Financial Officer



  

SIGNATURE PAGE TO AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	PITANGO HEALTHTECH FUND I - ISRAEL L.P 
		
	By:	 	/s/ Ittai Harel
		
	Name:	 	 
		
	Title:	 	 


  

			
	PITANGO HEALTHTECH FUND I, L.P.
		
	By:	 	/s/ Ittai Harel
		
	Name:	 	 
		
	Title:	 	 


  

			
	PITANGO HEALTHTECH PRINCIPALS FUND I, L.P.
		
	By:	 	/s/ Ittai Harel
		
	Name:	 	 
		
	Title:	 	 



  

SIGNATURE PAGE TO AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GV 2017, L.P.


 
			
		
	By:	 	GV 2017 GP, L.P., its General Partner
	By:	 	GV 2017 GP, L.L.C., its General Partner


 
			
		
	By:	 	/s/ Daphne M. Chang
	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory


  

			
	GV 2019, L.P.


 
			
		
	By:	 	GV 2019 GP, L.P., its General Partner
	By:	 	GV 2019 GP, L.L.C., its General Partner


 
			
		
	By:	 	/s/ Daphne M. Chang
	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory



  

SIGNATURE PAGE TO AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 













 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	G&H PARTNERS
		
	By:	 	/s/ Stefan J. Palmer Jr.
	Name:	 	     Stefan J. Palmer Jr.
	Title:	 	General Partner



  

SIGNATURE PAGE TO AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 













 SCHEDULE A 

INVESTORS 
  

			
	 Name and Address
	 	 
	 Novartis Institutes for Biomedical Research, Inc.

250 Massachusetts Avenue
 Cambridge, MA 02139

Attn: General Counsel
	 	
		
	 Timothy Joseph Barberich
 88 Beacon
Street, #3
 Boston, MA 02108
 tbarberich@aol.com
	 	
		
	 Longwood Fund IV, L.P.
 c/o Longwood
Fund
 The Prudential Tower
 800 Boylston St., Suite 1555

Boston, MA 02199
	 	
		
	 Bessemer Venture Partners IX, L.P.
 c/o
Bessemer Venture Partners
 1865 Palmer Avenue
 Suite 104

Larchmont, NY 10538
 Tel. 914-833-5300
 Transactions@bvp.com
	 	
		
	 Bessemer Venture Partners IX Institutional L.P.

c/o Bessemer Venture Partners
 1865 Palmer Avenue

Suite 104
 Larchmont, NY 10538

Tel. 914-833-5300

Transactions@bvp.com
	 	
		
	 Novartis Bioventures Ltd.
 Novartis
Campus, Forum 1-1.32
 Attn: Stephan Sandmeier

CH-4056 Basel, Switzerland

Email: nvf.notifications@nvfund.com
  

With a Copy to:
 Novartis Venture Fund

Attn: Nandita Shangari
 196 Broadway, 1st Floor

Cambridge, MA 02139
 Email: nandita.shangari@nvfund.com
	 	
		
	 GV 2017, L.P.
 Attn: GV Legal
Department
 1600 Amphitheatre Parkway
 Mountain View, CA
94043
 Email: notice@gv.com
	 	
		
	 GV 2019, L.P.
 Attn: GV Legal
Department
 1600 Amphitheatre Parkway
 Mountain View, CA
94043
 Email: notice@gv.com
	 	














			
	 6 Dimensions Capital, L. P.
 Attn:
Christina Chung
 8th Floor, 55 Cambridge Parkway,

Cambridge, MA 02142
 Tel:
825-2805 1580
 Email: christina.chung@6dimensionscapital.com

 
	 	
	 6 Dimensions Affiliates Fund, L.P.
 Attn:
Christina Chung
 8th Floor, 55 Cambridge Parkway,

Cambridge, MA 02142
 Tel:
825-2805 1580
 Email: christina.chung@6dimensionscapital.com

 
	 	
	 Pitango Healthtech Fund I, L.P. 

11 HaMenofim St., Herzliya 46725, Israel 
 Attention: Ittai
Harel (ittai.h@pitango.com) and Adv. Elana Barzilay (elana.b@pitango.com)
  
	 	
	 Pitango Healthtech Principals Fund I, L.P. 

11 HaMenofim St., Herzliya 46725, Israel 
 Attention: Ittai
Harel (ittai.h@pitango.com) and Adv. Elana Barzilay (elana.b@pitango.com)
  
	 	
	 Seth A. Rudnick 2014 Irrevocable GST Trust 

PO Box 5341
 Pinehurst, NC 28374 

Attn: Carolyn Rudnick
  
	 	
	 G&H Partners 
 1200 Seaport
Blvd. 
 Redwood City, CA 94063
  
	 	
	 Astellas Venture Management LLC
 2882
Sand Hill Road, Suite 121
 Menlo Park, CA 94025

shunichiro.matsumoto@astellas.com
  
	 	
	 667, L.P.
 Baker Brothers Life
Sciences, L.P.
 860 Washington St., 3rd Floor
 New York, NY
10014
  
 With a Copy to (which shall not constitute notice):

Wilmer Cutler Pickering Hale and Dorr LLP
 Attn: Jason Kropp

,60 State Street,
 Boston, MA 02109,

Email: Jason.Kropp@wilmerhale.com
  
	 	
	 RA Capital Healthcare Fund, L.P.
 RA
Capital Nexus Fund II, L.P.
 c/o RA Capital Management, L.P.

200 Berkeley Street
 18th Floor
 Boston, MA 02116

Attn: General Counsel
	 	














			
	 JMD III Holdings Limited
 c/o Citco Fund
Services (Cayman Islands) Limited
 89 Nexus Way, Camana Bay, P.O. Box 31106

Grand Cayman KY1-1205, Cayman Islands
  
	 	
	 BlackRock Health Sciences Trust II
 c/o
BlackRock Advisors, LLC
 60 State Street, 19th/20th Floor

Boston, MA 02109
 Attn: Erin Xie
	 	
		
	Gebrian Family Trust